122 related articles for article (PubMed ID: 31112981)
1. Atypical Chronic Myeloid Leukemia in a Patient with Aplastic Anemia.
Santopietro M; Miano M; Palumbo G; Zhang K; Cardarelli L; Chiaretti S; Peragine N; Nanni M; Diverio D; Mancini F; Testi AM; Moleti ML; Foà R; Giona F
Acta Haematol; 2019; 142(3):185-186. PubMed ID: 31112981
[No Abstract] [Full Text] [Related]
2. Treatment of aplastic anemia with antithymocyte globulin, cyclosporin A, methylprednisolone, danazol and recombinant human granulocyte-colony stimulating factor.
Shichino H; Mugishima H; Takamura M; Shimada T; Suzuki T; Chin M; Harada K; Ryo S; Kojima S
Acta Paediatr Jpn; 1996 Dec; 38(6):644-7. PubMed ID: 9002302
[TBL] [Abstract][Full Text] [Related]
3. Mini-ICE regimen allows mobilization of peripheral blood progenitor cells in a patient with chronic myelogenous leukemia failing the ICE protocol.
Salar A; Sureda A; Menéndez B; Sierra J
Haematologica; 2000 Mar; 85(3):326-7. PubMed ID: 10702830
[No Abstract] [Full Text] [Related]
4. Idarubicin-containing regimen and G-CSF are capable of recruiting CD34+/DR- cells with high proliferative potential which sustain Ph-negative polyclonal hematopoiesis.
Carella AM; Podestá M; Pollicardo N; Pungolino E; Raffo MR; Ferrero R; Bergamaschi G; Rosti V; Cazzola M; Saglio G
Leukemia; 1994 Jan; 8(1):212-3. PubMed ID: 7507192
[No Abstract] [Full Text] [Related]
5. Gene expression profiles of two accelerations in a CML patient.
Fiser K; Klamová H; Moravcová J
Leuk Res; 2006 Jun; 30(6):751-3. PubMed ID: 16289682
[No Abstract] [Full Text] [Related]
6. Clinical significance of development of Philadelphia-chromosome negative clones in patients with chronic myeloid leukemia treated with imatinib mesylate.
Perel JM; McCarthy C; Walker O; Irving I; Williams B; Kennedy GA
Haematologica; 2005 Nov; 90 Suppl():ECR25. PubMed ID: 16266916
[No Abstract] [Full Text] [Related]
7. Comparison of long-term outcomes between children with aplastic anemia and refractory cytopenia of childhood who received immunosuppressive therapy with antithymocyte globulin and cyclosporine.
Hama A; Takahashi Y; Muramatsu H; Ito M; Narita A; Kosaka Y; Tsuchida M; Kobayashi R; Ito E; Yabe H; Ohga S; Ohara A; Kojima S
Haematologica; 2015 Nov; 100(11):1426-33. PubMed ID: 26273061
[TBL] [Abstract][Full Text] [Related]
8. [Induction of Ph-negative normal clone and long-term survival by combined treatment with G-CSF plus middle dose cytosine arabinoside for patients with chronic myeloid leukemia in blastic transformation].
Katagiri T; Miyazawa K; Uchida Y; Hayashi S; Iwama H; Shyohji N; Kawakubo K; Shimamoto T; Inatomi Y; Kuriyama Y; Yaguchi M; Nehashi Y; Ohyashiki K; Toyama K
Rinsho Ketsueki; 1998 Dec; 39(12):1149-56. PubMed ID: 10028846
[TBL] [Abstract][Full Text] [Related]
9. Next-generation medicine: combining BCR-ABL and Hedgehog-targeted therapies.
Dao KH; Tyner JW
Clin Cancer Res; 2013 Mar; 19(6):1309-11. PubMed ID: 23382113
[TBL] [Abstract][Full Text] [Related]
10. Idarubicin, intermediate-dose cytarabine, etoposide, and granulocyte-colony-stimulating factor are able to recruit CD34+/HLA-DR- cells during early hematopoietic recovery in accelerated and chronic phases of chronic myeloid leukemia.
Carella AM; Frassoni F; Podestá M; Pungolino E; Pollicardo N; Ferrero R; Soracco M
J Hematother; 1994; 3(3):199-202. PubMed ID: 7530135
[TBL] [Abstract][Full Text] [Related]
11. Chemotherapy plus ponatinib: a new standard for Ph-positive ALL?
Thomas X
Lancet Oncol; 2015 Nov; 16(15):1451-1453. PubMed ID: 26432047
[No Abstract] [Full Text] [Related]
12. Hyperleukocytotic secondary acute myeloid leukemia (AML) with sole monosomy 7 as sequela of Philadelphia-chromosome positive chronic myeloid leukemia (CML).
Hackanson B; Rückert A; Lübbert M
Eur J Haematol; 2009 Dec; 83(6):611-2. PubMed ID: 19682063
[No Abstract] [Full Text] [Related]
13. [Treatment of leukemia: discussion].
Nihon Naika Gakkai Zasshi; 1992 Jul; 81(7):1081-93. PubMed ID: 1383368
[No Abstract] [Full Text] [Related]
14. Treatment of an adolescent with chronic myeloid leukemia and the T315I mutation with ponatinib.
Nickel RS; Daves M; Keller F
Pediatr Blood Cancer; 2015 Nov; 62(11):2050-1. PubMed ID: 25939962
[No Abstract] [Full Text] [Related]
15. Early hemopoietic progenitors in the peripheral blood of patients with severe aplastic anemia (SAA) after treatment with antilymphocyte globulin (ALG), cyclosporin-A and G-CSF.
Bacigalupo A; Piaggio G; Podestà M; Tong J; Pitto A; Figari O; Benvenuto F; Vassallo F; Tedone E; Grassia L; Van Lint MT; Gualandi F; Hoffman R
Haematologica; 1997; 82(2):133-7. PubMed ID: 9175313
[TBL] [Abstract][Full Text] [Related]
16. [Recent issues and prospects of the treatment of aplastic anemia].
Nakao S
Rinsho Ketsueki; 2014 Jan; 55(1):5-11. PubMed ID: 24492031
[No Abstract] [Full Text] [Related]
17. [Chemotherapy of relapsed AML and ALL].
Nishikawa K
Rinsho Ketsueki; 1996 Aug; 37(8):647-50. PubMed ID: 8827871
[No Abstract] [Full Text] [Related]
18. Upfront low-dose ponatinib (15 mg/day) for multi-TKI resistant chronic myeloid leukemia.
Tefferi A
Hematol Oncol; 2018 Oct; 36(4):718-720. PubMed ID: 29901221
[No Abstract] [Full Text] [Related]
19. Combination of ponatinib with Hedgehog antagonist vismodegib for therapy-resistant BCR-ABL1-positive leukemia.
Katagiri S; Tauchi T; Okabe S; Minami Y; Kimura S; Maekawa T; Naoe T; Ohyashiki K
Clin Cancer Res; 2013 Mar; 19(6):1422-32. PubMed ID: 23319824
[TBL] [Abstract][Full Text] [Related]
20. [Successful treatment with combination of methylprednisolone, antilymphocyte globulin and cyclosporine in two cases of aplastic anemia].
Ishikawa Y; Arioka H; Kobayashi R; Naito H
Rinsho Ketsueki; 1992 Nov; 33(11):1697-702. PubMed ID: 1469786
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
